Nothing less than the opportunity for

DURABLE SKIN CLEARANCE
for plaque psoriasis patients^1,2

ULTIMMA-2 ULTIMMA-2

ULTIMMA-1 ULTIMMA-1

PASI 90 achieved by 81% of patients at 1 year^1,2

SKYRIZI 150 mg (n=294)
USTEKINUMAB (n=99)
PLACEBO (n=98)

Participants received treatment at Week 0, Week 4, and every 12 weeks thereafter

ULTIMMA-2 Study: PASI 90 achieved by 81% of patients at 1 year.

PASI 90 achieved by 82% of patients at 1 year^1,2

SKYRIZI 150 mg (n=304)
USTEKINUMAB (n=100)
PLACEBO (n=102)

Participants received treatment at Week 0, Week 4, and every 12 weeks thereafter

ULTIMMA-1 Study: PASI 90 achieved by 82% of patients at 1 year.

IN PATIENTS WHO ACHIEVED PASI 90 AT WEEK 16, 88% MAINTAINED PASI 90 AT 1 YEAR^1,2

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate Phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis.^1,2

NRI=nonresponder imputation; PASI 90=≥90% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician's Global Assessment of clear or almost clear.

CO-PRIMARY ENDPOINTS WERE PASI 90 AND sPGA 0/1 RESPONSE VS PLACEBO AT WEEK 16¹

sPGA 0/1 at Week 16^1,2:

UltIMMa-1:
SKYRIZI 88%, ustekinumab 63%, placebo 8%

UltIMMa-2:
SKYRIZI 84%, ustekinumab 62%, placebo 5%

Active Comparator

The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.

Before and after photos of SKYRIZI®- treated patients with moderate to severe plaque psoriasis from the UltIMMa-2 study with PASI 90 clearance.

Patient case study representing

IMPROVEMENT WITH SKYRIZI³

Photos of SKYRIZI-treated patients with moderate to severe plaque psoriasis from the UltIMMa-2 study

BASELINE

PASI OF TRUNK=32

AFTER 2 DOSES

WEEK 16 – PASI=4

88%

PASI IMPROVEMENT FROM BASELINE*

2 doses Week 16 PASI improvement of chest

2 doses Week 16 PASI improvement of back

AFTER 5 DOSES

WEEK 52 – PASI=1

97%

PASI IMPROVEMENT FROM BASELINE

5 doses Week 52 PASI improvement of chest

5 doses Week 52 PASI improvement of back

*Case does not represent PASI 90 response at Week 16.

Considering SKYRIZI
for your patients?

See what coverage for SKYRIZI looks like.

VIEW ACCESS

Man in a blue swimsuit raises his hands in celebration

Already familiar
with SKYRIZI?

Find frequently used forms for your office.

VIEW RESOURCES

CO-PRIMARY ENDPOINTS WERE PASI 90 AND sPGA 0/1 RESPONSE VS PLACEBO AT WEEK 16¹

sPGA 0/1 at Week 16^1,2:

UltIMMa-1:
SKYRIZI 88%, ustekinumab 63%, placebo 8%

UltIMMa-2:
SKYRIZI 84%, ustekinumab 62%, placebo 5%

Active Comparator

ULTIMMA-2 ULTIMMA-2

ULTIMMA-1 ULTIMMA-1

PASI 100 achieved by 60% of patients at 1 year^1,2

SKYRIZI 150 mg (n=294)
USTEKINUMAB (n=99)
PLACEBO (n=98)

Participants received treatment at Week 0, Week 4, and every 12 weeks thereafter

ULTIMMA-2 Study: PASI 100 achieved by 60% of patients at 1 year.

PASI 100 achieved by 56% of patients at 1 year^1,2

SKYRIZI 150 mg (n=304)
USTEKINUMAB (n=100)
PLACEBO (n=102)

Participants received treatment at Week 0, Week 4, and every 12 weeks thereafter

ULTIMMA-1 Study: PASI 100 achieved by 56% of patients at 1 year.

IN PATIENTS WHO ACHIEVED PASI 100 AT WEEK 16, 80% MAINTAINED PASI 100 AT 1 YEAR¹

STUDY DESIGN:

NRI=nonresponder imputation; PASI 100=100% improvement in Psoriasis Area and Severity Index; sPGA 0/1=static Physician's Global Assessment of clear or almost clear.

Patient case study representing

IMPROVEMENT WITH SKYRIZI³

Before and after photos of SKYRIZI-treated patients with moderate to severe plaque psoriasis from the UltIMMa-2 study

BASELINE

PASI OF TRUNK=40

AFTER 2 DOSES

WEEK 16 – PASI=0

100%

PASI IMPROVEMENT FROM BASELINE

AFTER 5 DOSES

WEEK 52 – PASI=0

100%

PASI IMPROVEMENT FROM BASELINE

PRESCRIBED Branded SYSTEMIC
BY DERMATOLOGISTS FOR PATIENTS
WITH PSORIATIC DISEASE

#1 PRESCRIPTION ANALYSIS CALCULATED BY COMBINED PRESCRIPTION DATA ACROSS
Ps AND PsA

For patients with psoriatic disease, deﬁned as those with plaque psoriasis or psoriatic arthritis.
Source of data: Integrated Symphony Health as of 9/2023.⁴ The term branded systemic is defined as systemic drugs that are sold by a specific name or trademark and protected by patent. This analysis did not include over-the-counter (OTC) medications.

Nothing less than the opportunity for CONSISTENT PASI 90/100 RATES UP TO ~6 YEARS⁵

PASI 90 and PASI 100 achievement at week 304 in
the open-label extension (OLE)⁵

INTEGRATED RESULTS FROM UltIMMa-1 AND UltIMMa-2
ALL DATA ARE AS OBSERVED

The data presented here are a subanalysis of the LIMMitless OLE and include only patients from UltIMMa-1 and -2 who were originally randomized to SKYRIZI, completed the RCT, and enrolled in the OLE. LIMMitless is an ongoing open-label extension for which patients who completed either UltIMMa trial, IMMvent, or IMMhance were eligible to participate.^5-7

PASI 90 AND PASI 100 RESPONSE RATES MAINTAINED AT WEEK 304 (OLE) (AS OBSERVED DATA)⁵

OLE LIMITATIONS: In an open-label extension, there is a potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.

AO DISCLOSURE: In an as observed analysis (AO), missing visit data were excluded from calculations for that visit, which may increase the percent of responders. All observed data were used regardless of premature discontinuation of study drug, initiation of concomitant medication, or rescue medication. The same patient may not have a response at each timepoint.

STATISTICAL METHODOLOGY: Regardless of how missing data were handled, results were consistent at timepoints evaluated.

STUDY DESIGN:

LIMMitless is an ongoing, single-arm, multicenter, open-label extension of Phase 2 and 3 studies evaluating the long-term efficacy and safety of SKYRIZI (150 mg). Patients who completed UltIMMa-1 or -2, IMMvent, or IMMhance were eligible to participate.^5-7

ON AVERAGE, PATIENTS SAW 58% CLEARER SKIN
4 WEEKS AFTER 1ST DOSE^5,9 INTEGRATED RESULTS FROM UltIMMa-1 AND UltIMMa-2 AT SPECIFIC TIMEPOINTS

After 1 dose
Week 4

58^%

MEAN PASI IMPROVEMENT*^†

(n=598)

VS 9% for placebo

(n=200)

PASI 90 AT Week 4 was 6%

After 2 doses
Week 16

91^%

MEAN PASI IMPROVEMENT*^†

(n=598)

VS 10% for placebo

(n=200)

PASI 90 AT Week 16 was 75%

After 5 doses
Week 52

95^%

MEAN PASI IMPROVEMENT*^†

(n=598)

placebo N/A

()

PASI 90 AT Week 52 was 81%

Open-Label Extension (OLE), AS OBSERVED⁵

After 26 doses
Week 304

97^%

MEAN PASI IMPROVEMENT^†

(n=374)

Placebo N/A

()

MAINTENANCE OF RESPONSE¹: 88% of PASI 90 responders at Week 16 maintained response at Week 52.

*As measured by change in PASI score from baseline; analysis conducted using last observation carried forward (LOCF) method.

Regardless of how missing data were handled, results were consistent at timepoints evaluated.

LIMITATIONS: Mean change in PASI at all timepoints and PASI 90 response at Week 4 were prespecified, nonranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.

LIMMitless is an open-label extension for which patients who completed UltIMMa-1 or -2, IMMvent, or IMMhance were eligible to participate. The data presented here are a subanalysis of LIMMitless and include only patients from UltIMMa-1 and -2. 525 patients from UltIMMa-1 and -2 have enrolled in LIMMitless at this time.^5-7

STUDY DESIGNS:

^†Mean PASI improvement is an assessment of the average improvement from baseline to a set point in time in psoriatic signs of redness, thickness, scale, and body surface area of involvement.¹⁰